SynthesisJournal of medical virology2023
Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis.
Synthesis in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis.Journal of medical virology · 2023Pooled it
- Peripheral immune cell profiles and tumor marker expression in high-risk HPV-infected cervical lesions: a comparative study.Frontiers in oncology · 2026Article
- Advances in Cervical Cancer Diagnostics Based on Immunosensors: Innovative Approaches and Tumor Biomarkers.Current topics in medicinal chemistry · 2026Review
- Integrating Biomarkers into Cervical Cancer Screening-Advances in Diagnosis and Risk Prediction: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Online Conference "Chronic Viral Infections and Cancer, Openings for Vaccines and Cure" VIRCAN2024, Monitoring the Progress.Vaccines · 2025Article
- Molecular Insights into HPV-Driven Cervical Cancer: Oncoproteins, Immune Evasion, and Epigenetic Modifications.Microorganisms · 2025Review
- Enhancing Cervical Cancer Screening: New Diagnostic Methodologies, Triage, and Risk Stratification in Prevention and Treatment.Life (Basel, Switzerland) · 2025Review
- HPV and Cervical Cancer-Biology, Prevention, and Treatment Updates.Current oncology (Toronto, Ont.) · 2025Review
- Serum profiling of the antibody response to HPV in women with or without abnormal cervical cytology undergoing cervical cancer screening.Frontiers in immunology · 2025Article
- The potential role of miR-155 in the tumorigenesis of cervical cancer.Frontiers in cell and developmental biology · 2025Review
- Genetic variability of human papillomavirus type 18 based on E6, E7 and L1 genes in central China.Virology journal · 2024Article
- The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy.Frontiers in oncology · 2024Review
- Deep feature extraction and fine κ-nearest neighbour for enhanced human papillomavirus detection in cervical cancer - a comprehensive analysis of colposcopy images.Contemporary oncology (Poznan, Poland) · 2024Article
- Human papillomavirus is an important risk factor for esophageal carcinoma in a Chinese population.Journal of cancer research and clinical oncology · 2023Article
- Prolidase-proline oxidase axis is engaged in apoptosis induction by birch buds flavonol santin in endometrial adenocarcinoma cell line.Frontiers in molecular biosciences · 2023Article
- Oncogenic roles and related mechanisms of the long non-coding RNA MINCR in human cancers.Frontiers in cell and developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 6 countries.
Funding
Abstract
We reviewed the literature on the importance of selected anti-high-risk human papillomavirus (HR-HPV) antibodies (namely, 16/18 and early oncoproteins E6 and E7) as potential serological markers for early detection of individuals at high risk of cervical cancer. We searched for studies in PubMed and Embase databases published from 2010 to 2020 on antibodies against HR-HPV E6 and E7 early proteins and cervical cancer. Pooled sensitivity and specificity for HPV16 and HPV18 antibodies were calculated using a bivariate hierarchical random-effects model. A total of 69 articles were identified; we included three studies with 1550 participants. For the three HPV16/18 E6 and E7 antibody tests, enzyme-linked immunosorbent assay-based assays had a sensitivity of 18% for detecting CIN2+ (95% confidence interval [CI]: 15-21) and a specificity of 96% (95% CI: 92-98), for slot-blot, sensitivity was 28.9% (95% CI: 23.3-35.1) and specificity was 72% (95% CI: 66.6-77.0) for detecting CIN2+, and for multiplex HPV serology assay based on a glutathione S-transferase, sensitivity was 16% (95% CI: 8.45-28.6) and specificity was 98% (95% CI: 97-99) for detecting invasive cervical cancer. HR-HPV16/18 E6 and E7 serological markers showed high specificity, but sensitivity was suboptimal for the detection of cervical cancer in either population screening settings or as point-of-care screening tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.